186 related articles for article (PubMed ID: 10581347)
1. [The influences of genetic and environmental factors on plasma plasminogen activator inhibitor-1 levels in patients with essential hypertension].
Song Y; Xu W; Chen Y; Che L; Wang Q; Zhou X; Wu J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1999 Dec; 16(6):374-6. PubMed ID: 10581347
[TBL] [Abstract][Full Text] [Related]
2. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
[TBL] [Abstract][Full Text] [Related]
3. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
[TBL] [Abstract][Full Text] [Related]
4. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.
Sartori MT; Vettor R; De Pergola G; De Mitrio V; Saggiorato G; Della Mea P; Patrassi GM; Lombardi AM; Fabris R; Girolami A
Thromb Haemost; 2001 Nov; 86(5):1161-9. PubMed ID: 11816701
[TBL] [Abstract][Full Text] [Related]
5. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
Nowakowska A
Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
[TBL] [Abstract][Full Text] [Related]
6. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
[TBL] [Abstract][Full Text] [Related]
8. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
10. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor 1 expression in platelets is not influenced by the 4G/5G promoter polymorphism.
Brogren H; Wallmark K; Jern S; Karlsson L
Thromb Res; 2008; 121(6):793-7. PubMed ID: 17884148
[TBL] [Abstract][Full Text] [Related]
12. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
Kinik ST; Ataç FB; Verdi H; Cetintaş S; Sahin FI; Ozbek N
Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
[TBL] [Abstract][Full Text] [Related]
13. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction.
Doggen CJ; Bertina RM; Cats VM; Reitsma PH; Rosendaal FR
Thromb Haemost; 1999 Jul; 82(1):115-20. PubMed ID: 10456464
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between the 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and the pathogenesis of pregnancy-induced hypertension syndrome].
Guan LX; Du XY; Wang JX; Wang RL; Wu ZL; Jiang H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Apr; 21(2):173-5. PubMed ID: 15079805
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression.
Ramón LA; Gilabert-Estellés J; Cosín R; Gilabert J; España F; Castelló R; Chirivella M; Romeu A; Estellés A
Thromb Res; 2008; 122(6):854-60. PubMed ID: 18423526
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.
Testa R; Bonfigli AR; Sirolla C; Marra M; Boemi M; Mari D; Sacchi E; Dolci A; Catalano A; Procopio A; Ceriello A
Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):220-6. PubMed ID: 17433639
[TBL] [Abstract][Full Text] [Related]
17. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
[TBL] [Abstract][Full Text] [Related]
18. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.
Ye S; Green FR; Scarabin PY; Nicaud V; Bara L; Dawson SJ; Humphries SE; Evans A; Luc G; Cambou JP
Thromb Haemost; 1995 Sep; 74(3):837-41. PubMed ID: 8571307
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
20. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
Ezzidi I; Mtiraoui N; Chaieb M; Kacem M; Mahjoub T; Almawi WY
Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]